ScreenerHero

AVLN Avalyn Pharma Inc.

NAS · US · Healthcare · Biotechnology · avalynpharma.com
25.53USD+0.39%Mkt Cap: 1.13B $P/E: —

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company pr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.13B USD
Enterprise Value792.07M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-85.20M USD
Revenue/Share—
Last Price25.53 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.38
PEG—
EV/EBITDA-7.21
EV/Revenue—
P/S—
P/B2.83
EPS (TTM)-2.32
EPS (Forward)-1.90
52W Range
24.159% of range40.17
52W High40.17 USD
52W Low24.15 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE35.70%
ROA-57.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.48M USD
CapEx (TTM)344.00K USD
FCF Margin—
FCF Yield—
Net Debt-335.32M USD
Net Debt/EBITDA3.05
Balance Sheet
Debt/Equity-0.01
Current Ratio33.12
Quick Ratio32.76
Book Value/Sh8.98 USD
Cash/Share7.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)61.80 USD
Upside (mean)+142.1%
Target Range52.00 USD – 80.00 USD
52.00+142.1% to mean80.00
# Analysts5
Ownership
Shares Out.44.33M
Float27.41M
Insiders0.00%
Institutions103.99%
Short Interest
Short Ratio10.7d
Short % Float4.72%
Short % Out.4.72%
Shares Short2.09M
Short (prev mo.)2.07M
Technical
SMA 5033.29 (-23.3%)
SMA 20030.82 (-17.2%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)271.01K
Avg Vol (10d)328.22K
Technical Indicators
RSI (14)30.9
MACD-2.2105
MACD Signal-1.7544
MACD Hist.-0.4562
BB Upper36.75 USD
BB Middle30.25 USD
BB Lower23.75 USD
BB Width42.96%
ATR (14)2.017 USD
Vol Ratio (20d)0.67x